American Chemical Society's weekly PressPac -- Ja...(ead to the design of new medications for...)

Celiac disease is a condition in which the stomach cannot properly digest wheat and other gluten-containing foods. The disease afflicts an estimated 2 million people in the United States alone.

In the article, C&EN Deputy Assistant Managing Editor Stu Borman notes that the disease is believed to occur when the protein gluten interacts with an enzyme called transglutaminase 2 (TG2), triggering an autoimmune reaction that damages the small intestine and causes diarrhea, abdominal pain and other symptoms. As a result, people with the disease are urged to follow a strict gluten-free diet.

Although scientists have previously obtained the X-ray crystal structure of human TG2, they have only revealed its closed or inactive form, the article points out. Now, Chaitan Khosla and colleagues at Stanford University report the first-ever determination of the open structure of the enzyme, in which its active site is accessible to substrates. The finding that could help scientists design inhibitors of the enzyme that could serve as medications for celiac disease and other related conditions, according to the article.

ARTICLE #5 EMBARGOED FOR 9 A.M., EASTERN TIME, Jan. 7, 2008 Enzyme opens for business

This story will be available on Jan. 7 at http://pubs.acs.org/cen/

FOR ADVANCE INFORMATION, CONTACT:
Michael Bernstein
ACS News Service
Phone: 202-872-6042
Fax: 202-872-4370
Email: m_bernstein@acs.org

Bytesize Science, a podcast for young listeners
http://feeds.feedburner.com/bytesizescience

The American Chemical Society (ACS) Office o
'/>"/>